Skip to main content
ADVANCED SEARCH
Log in
Top
Ophthalmology and Therapy
Published in:

Open Access 19-05-2025 | Atropine | Correction

Correction: The Macular Choroidal Thickness in Danish Children with Myopia After Two-Year Low-Dose Atropine and One-Year Wash-Out: A Placebo-Controlled, Randomized Clinical Trial

Authors: Niklas C. Hansen, Anders Hvid-Hansen, Toke Bek, Flemming Møller, Nina Jacobsen, Line Kessel

Published in: Ophthalmology and Therapy | Issue 7/2025

Login to get access
Metadata
Title
Correction: The Macular Choroidal Thickness in Danish Children with Myopia After Two-Year Low-Dose Atropine and One-Year Wash-Out: A Placebo-Controlled, Randomized Clinical Trial
Authors
Niklas C. Hansen
Anders Hvid-Hansen
Toke Bek
Flemming Møller
Nina Jacobsen
Line Kessel
Publication date
19-05-2025
Publisher
Springer Healthcare
Keywords
Atropine
Myopia
Published in
Ophthalmology and Therapy / Issue 7/2025
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-025-01154-7

Other articles of this Issue 7/2025

Transepithelial Versus Conventional PRK: A Randomized Controlled Study

The Natural History of Acanthamoeba Keratitis: A Systematic Literature Review

How effective is AMT in repairing the ocular surface?

Surgical Outcomes of Retropupillary Iris-Claw Intraocular Lens Implantation for Various Indications

Pooled Analysis of Three MicroShunt Studies in Primary Open-Angle Glaucoma Evaluating Different Concentrations of Applied Mitomycin C

  • Open Access
  • Glaucoma
  • ORIGINAL RESEARCH

Symptomology and Impact of Dry Eye Disease: A Patient and Physician Perspective

Raising the standard: ensuring patient safety through minimum requirements for CGM performance

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Watch the full video

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025: the 85th Scientific Sessions

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s annual meeting.

Read more
Image Credits